Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 1/20 | 0.46 | |
| ▸ | NTMT1 | Q9BV86 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 11/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 9/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 9/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 9/20 | 0.41 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427848 | 1.00 | PDF (0.46) | PDFNTMT1F2PRSS1PRSS2 | |
| Acetic Acid SCHEMBL16234756 | 0.98 | PDF (0.44) | PDFNTMT1F2PRSS1PRSS2 | |
| SCHEMBL1100531 | 0.90 | PDF (0.49) | PDFNTMT1F2SSTR3TACR1 | |
| SCHEMBL1498278 | 0.90 | F2 (0.42) | NTMT1F2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL29388894 | 0.90 | ITGB1 (0.45) | F2PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL11528157 | 0.89 | F2 (0.42) | NTMT1F2PRSS1PRSS2PRSS3 | |
| Acetic Acid SCHEMBL3507728 | 0.88 | F2 (0.41) | F2PRSS1PRSS2PRSS3TACR1 | |
| SCHEMBL5582769 | 0.85 | NTMT1 (0.53) | PDFNTMT1F2SSTR3TACR1 | |
| SCHEMBL3239444 | 0.85 | F2 (0.46) | NTMT1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL11417445 | 0.85 | NTMT1 (0.55) | PDFNTMT1F2SSTR3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | IPSEN BIOPHARM LIMITED (GB) | 2026-03-31 | — | — | US | disclosed |
| EP-4326869-A1 | RECOMBINANT MIROPIN | University of Louisville (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20240051991-A1 | Recombinant Miropin | UNIV OF LOUISVILLE (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2022226451-A1 | RECOMBINANT MIROPIN | UNIVERSITY OF LOUISVILLE (US) | 2022-10-27 | — | — | WO | disclosed |
| US-20220211823-A1 | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | IPSEN BIOPHARM LIMITED (GB) | 2022-07-07 | — | — | US | disclosed |
| WO-2018146171-A1 | METHODS FOR TREATING MAST CELL ACTIVATION DISEASES | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-08-16 | — | — | WO | disclosed |
| US-8153413-B2 | High alkaline protease and use thereof | JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8133485-B2 | Immunoglobulin specifi for mast cell immunoglobulin receptor (IRp60) for use in treatment and prevention of allergic disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2012-03-13 | — | — | US | disclosed |
| EP-1730194-B1 | BI-SPECIFIC ANTIBODIES FOR TARGETING CELLS INVOLVED IN ALLERGIC-TYPE REACTIONS, COMPOSITIONS AND USES THEREOF | YISSUM RES DEV CO (IL) | 2011-11-02 | — | — | EP | disclosed |
| US-7897364-B2 | Method for determining inhibitors of neurotrypsin | UNIVERSITY OF ZURICH (CH) | 2011-03-01 | — | — | US | disclosed |
| WO-1996009297-A1 | COMPOSITIONS AND METHODS FOR TREATING MAST-CELL INFLAMMATORY CONDITION | ARRIS PHARMACEUTICAL CORPORATION (US) | 1996-03-28 | — | — | WO | disclosed |
| US-5427931-A | Useful in the treatment and detection of Alzheimer's disease | THEN REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-06-27 | — | — | US | disclosed |
| US-5411978-A | Aging resistance, human skin | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1995-05-02 | — | — | US | disclosed |
| US-5338747-A | Benzoisothiazolinone-1-dioxide derivatives as elastase inhibitors | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1994-08-16 | — | — | US | disclosed |
| US-5314815-A | Method for temporarily inhibiting or deactivating serine hydrolase and adduct of serine hydrolase with a phosphonate or phosphate compound | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1994-05-24 | — | — | US | disclosed |
| EP-0527823-A4 | — | — | 1994-04-06 | — | — | EP | disclosed |
| US-5281523-A | Adduct of serine hydrolase and nitrophenyl pnenacyl phosphonate | THE CATHOLIC UNIVERSITY OF AMERICA (US) | 1994-01-25 | — | — | US | disclosed |
| US-5270165-A | Diagnosing Alzheimer's disease | THE REAGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-12-14 | — | — | US | disclosed |
| EP-0527823-A1 | PURIFICATION, DETECTION AND METHODS OF USE OF PROTEASE NEXIN-2 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-02-24 | — | — | EP | disclosed |
| EP-0446047-A1 | Benzisothiazolinone-1-dioxide derivatives as elastase inhibitors | UNILEVER PLC (GB) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589139-B2 | Clostridial neurotoxins comprising an exogenous activation loop | PDXK, VIP, F13B | PDF 335/4885NTMT1 1622/4885F2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.